Resalis Therapeutics Srl closed a €10 million (US$10.6 million) seed round to progress toward the clinic a micro-RNA (miR) inhibitor in development for metabolic disease indications. Riccardo Panella, chief scientific officer and founder, identified the potential of a particular miR species, miR-22, as a target for metabolic syndrome while conducting studies on its potential role in oncology while at Harvard Medical School and Beth Israel Deaconess Medical Center.

Previa Medical SA will begin clinical trials later this year of its artificial intelligence software designed for early detection of sepsis after it raised €2.1 million (US $2.2 million) in seed funds.

Vevo Therapeutics Inc. raised $12 million in an over-subscribed seed round to build out an in vivo single-cell screening platform, which will enable it to interrogate simultaneously the effects of small molecule drug leads on multiple cancer cell lines.

Newco Vacv Biotherapeutics Ltd. has raised $3 million in a seed round to complete preclinical development of next-generation oncolytic viruses that are engineered to overcome previous shortcomings of this modality.

Axoft Inc. emerged from stealth mode with an $8 million seed round led by The Engine, the Massachusetts Institute of Technology’s venture spinout for early-stage tech startups. The funds will be used to conduct preclinical studies and scale up prototypes of its supple brain implant technology.

Cleara Biotech BV has closed a $2.5 million seed financing round, the proceeds of which will be used to progress its compounds toward clinical development and build the company's developmental pipeline.

Carver Biosciences Inc., a company focused on the development of CRISPR/Cas13 antivirals, has closed a seed round of funding.